EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma

Julia Ayumi Ikeda Kawasaki, Ariane Pereira de Souza, João Pedro Rocha Pontes, Juliana Mara Serpeloni, Janaina Nicolau de Oliveira, André Luís Laforga Vanzela, Fernando Terziotti, Wilner Martinez-Lopez, Karen Brajão de Oliveira, Roberta Losi Guembarovski

Molecular Biology Reports · 2026

DOI: 10.1007/s11033-026-12697-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Biology Reports, 2026. Verfasst von Julia Ayumi Ikeda Kawasaki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-bcl-2, Urinary Bladder Neoplasms. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universidade Estadual De Londrina.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Urothelial bladder carcinoma (UBC) is the ninth most common malignancy worldwide and ranks thirteenth in cancer-related mortality. A significant challenge in managing non-muscle-invasive UBC (NMIBC) is the high recurrence rate, compounded by a paucity of robust prognostic biomarkers. Given that evasion of apoptosis is a hallmark of carcinogenesis, the apoptosis regulator BCL-2 oncogene plays a critical role by negatively regulating the intrinsic apoptotic pathway, often leading to protein overexpression and malignant cell immortalization. Methods and Results: This study evaluated the BCL-2 allelic variants rs2279115 (G > T) and rs3943258 (T > C), including their haplotype structures, in association with BCL-2 immunohistochemical expression in UBC patients. Genetic and immunostaining data were analyzed alongside prognostic factors, environmental exposure, and clinical history. Furthermore, we sought to exhibit BCL-2 immunohistochemical staining patterns via immunofluorescence in selected samples. Our findings revealed that the rs2279115 variant is significantly associated with BCL-2 positive expression. Specifically, the TT genotype in the genotypic model ( p = 0.035) and the GT genotype in the overdominant model ( p = 0.045) were linked to protein status. Additionally, the CT haplotype was independently associated with high-grade tumors.

Conclusions

The presence of the CT haplotype — in either homozygosity or heterozygosity — exerted a risk effect of high-grade ( p = 0.020). In conclusion, these findings suggest that BCL-2 variants, haplotype structures, and immunohistochemical expression may offer relevant insights into the molecular characteristics of urothelial bladder cancer. Further prospective validation is needed to determine whether BCL-2 profiling can serve as a useful complementary tool for risk assessment in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Proto-Oncogene Proteins c-bcl-2Urinary Bladder NeoplasmsHumansFemaleMalePolymorphism, Single NucleotideNon-Muscle Invasive Bladder NeoplasmsPrognosisAgedGenotypeMiddle AgedHaplotypesAllelesGenetic Predisposition to DiseaseGene Expression Regulation, NeoplasticBiomarkers, TumorImmunohistochemistryApoptosis

Stichwörter der Autor:innen

Haplotype structuresImmunohistochemistrySingle nucleotide polymorphismTumor recurrenceUrothelial bladder carcinoma

Substanzen

Proto-Oncogene Proteins c-bcl-2BCL2 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil.
  • Laboratory of Molecular Genetics and Immunology, Department of Immunology, Parasitology and General Pathology, Londrina, PR, Brazil.
  • Laboratory of Cytogenetics and Plant Diversity, Department of General Biology, Londrina, PR, Brazil.
  • Londrina Cancer Hospital - HCL, Londrina, PR, Brazil.
  • Genetics Department and Biodosimetry Service, Instituto de Investigaciones Biológicas Clemente Estable, Montevideo, Uruguay.
  • Laboratory of Mutagenesis and Oncogenetics, Department of General Biology, State University of Londrina, Londrina, PR, Brazil. robertalosi@uel.br.

Förderung

  • Universidade Estadual De Londrina

Zitieren

APA

Kawasaki, J. A. I., de Souza, A. P., Pontes, J. P. R., Serpeloni, J. M., de Oliveira, J. N., Vanzela, A. L. L., Terziotti, F., Martinez-Lopez, W., de Oliveira, K. B., & Guembarovski, R. L. (2026). Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular Biology Reports. https://doi.org/10.1007/s11033-026-12697-8

Vancouver

Kawasaki JAI, de Souza AP, Pontes JPR, Serpeloni JM, de Oliveira JN, Vanzela ALL, et al. Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma. Molecular Biology Reports. 2026. doi:10.1007/s11033-026-12697-8

BibTeX
@article{Kawasaki2026,
  author = {Kawasaki, Julia Ayumi Ikeda and de Souza, Ariane Pereira and Pontes, João Pedro Rocha and Serpeloni, Juliana Mara and de Oliveira, Janaina Nicolau and Vanzela, André Luís Laforga and Terziotti, Fernando and Martinez-Lopez, Wilner and de Oliveira, Karen Brajão and Guembarovski, Roberta Losi},
  title = {Impact of BCL-2 rs2279115 and rs3943258 variants on protein expression and clinical outcome of urothelial bladder carcinoma},
  journal = {Molecular Biology Reports},
  year = {2026},
  doi = {10.1007/s11033-026-12697-8}
}
Kostenlos starten →